Sparks commentary - Oryzon Genomics

Healthcare

Sparks - Oryzon Genomics

More on this equity
testalize-me-0jE8ynV4mis-unsplash
Oryzon Genomics (BME: ORY) further strengthens vafidemstat’s intellectual property profile
Published by Arron Aatkar, PhD

Oryzon Genomics has received new ‘decision to grant’ communications from the Canadian Intellectual Property Office and the Israel Patent Office. This is for its patents ‘Methods of treating behavior alterations’ for lead CNS candidate, vafidemstat, as a potential treatment to address aggression and social withdrawal. Once granted, these patents will remain in force until at least 2038 in Canada and Israel, excluding any potential patent term extensions (which have the potential to add additional years of protection).

Oryzon is currently preparing for a Phase III programme, which will evaluate vafidemstat for the treatment of aggression in patients with borderline personality disorder.

Latest

Energy & Resources | Comment

bp (BP:LSE) – Updated Q225 guidance

Healthcare | Comment

Immix Biopharma (NASDAQ: IMMX) – Potential to expand NXC-201

TMT | Comment

WPP (LSE: WPP) – Weak Q2, reduces guidance

TMT | Comment

Celebrus (AIM: CLBS) outlines new strategic focus

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free